To The Moon

$Ultragenyx Pharmaceutical(RARE)$’s failed Angelman-syndrome trial removed a major pipeline asset and weakened confidence in conclusions drawn from its earlier studies. The company still has commercial products and regulatory catalysts, but their value must now be assessed alongside financing needs, spending reductions and heightened clinical uncertainty.

Ultragenyx announced on September 2 that the 129-patient Phase 3 Aspire study of apazunersen failed both its primary cognitive endpoint and key secondary multidomain endpoint. The company found no treated-versus-control difference supporting efficacy and said it would evaluate the programme’s disposition while implementing significant expense reductions. Ultragenyx’s official trial release gives the endpoint result and planned response.

This failure matters beyond one forecast. Earlier Phase 1/2 observations had suggested durable developmental improvement, but the randomised trial did not confirm it. That does not prove every Ultragenyx programme will fail, because the molecules and diseases differ. It does justify a higher discount for pipeline estimates that depend heavily on uncontrolled or small studies.

The bullish case is that Ultragenyx is not a single-asset company. For the second quarter reported August 4, total revenue was $214 million, including $156 million from Crysvita and $27 million from Dojolvi. Management retained full-year revenue guidance, and UX111 for Sanfilippo syndrome carries a September 19 FDA action date. The company’s second-quarter update describes the commercial base and remaining pipeline.

The bearish case is cash consumption and another binary decision arriving quickly. Cost cuts preserve liquidity but can slow research or commercial execution. An FDA delay or rejection for UX111 would compound the loss of apazunersen, while approval would still leave manufacturing, launch and reimbursement risk.

$Ultragenyx Pharmaceutical(RARE)$ fell 44.03% on September 3 to $14.85 after trading between $13.81 and $15 on 27 million shares, compared with 3.84 million the previous day. The gap created little established support. The session low near $13.80 is the first reference, followed by $12 and $10; resistance is $15 to $16 and then the gap area beginning near $20. The daily history confirms capitulation-level volume but does not establish that selling is finished.

Binary regulatory risk makes short premium hazardous. If RARE rebounds but cannot close above $16 before the FDA decision, an illustrative defined-risk bear call spread using a short $20 call and long $25 call could express continued resistance, only if expiry is chosen after considering the September 19 event and the live short-call delta is no greater than about 0.15. Maximum loss is $500 minus the credit. A sustained close above $20 would invalidate the structure.

The evidence leans bearish despite the commercial cushion. UX111 approval, credible expense reductions and a recovery above $20 would invalidate that stance. Another regulatory setback or loss of $13.80 would strengthen it. This is personal opinion for education, not financial advice or an instruction to enter a trade.